Literature DB >> 36107253

Primary hyperparathyroidism in pregnancy: experience of a tertiary centre.

Muhammad Fahad Arshad1,2, Maulee Hiromi Arambewela3,4, William M Bennet3, Monique Sterrenburg3, Saba P Balasubramanian5,3.   

Abstract

BACKGROUND AND
PURPOSE: The management of primary hyperparathyroidism (PHPT) during pregnancy is challenging and there is no clear consensus on whether it increases the risk of complications in pregnancy. We conducted this study to review the maternal and fetal outcomes of pregnant women treated for PHPT in a single centre.
METHODS: Data on relevant clinical parameters, demographics, management strategies, maternal and fetal outcomes were collected from the medical records of pregnant patients with PHPT diagnosed between 2012 and 2019.
RESULTS: Of 15 pregnant women with PHPT, 6 were managed medically and 9 underwent surgery. The median age at their index pregnancy was 28 years [range 19-42]. The median highest adjusted calcium level in the medical group was 2.90 [range 2.61-3.25] mmol/L vs. 3.11 [2.78-4.95] mmol/L in the surgical group. There was one miscarriage and the stillbirth of twins in the medical group, but no such outcomes in the surgical group. The median gestational ages were 39 + 3 weeks [range 24 + 2-41 + 2 weeks] and 39 + 4 weeks [range 37 + 1-39 + 5 weeks] in the medical and surgical groups, respectively. No birth was complicated by neonatal tetany or convulsions.
CONCLUSION: More complications developed in the pregnant PHPT patients who were managed medically than in those who underwent surgery. Surgery performed during the second trimester resulted in good outcomes. Multi-centre prospective studies are required to ascertain the risk of various complications in women with PHPT during pregnancy.
© 2022. The Author(s).

Entities:  

Keywords:  Hypercalcaemia; Pregnancy; Primary hyperparathyroidism; Surgery

Year:  2022        PMID: 36107253     DOI: 10.1007/s00595-022-02583-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.540


  3 in total

1.  Cinacalcet for hyperparathyroidism in pregnancy and puerperium.

Authors:  Carmen Horjus; Inge Groot; Darryl Telting; Petra van Setten; Adriaan van Sorge; Christopher S Kovacs; Ad Hermus; Hans de Boer
Journal:  J Pediatr Endocrinol Metab       Date:  2009-08       Impact factor: 1.634

2.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.

Authors:  John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

Review 3.  Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature.

Authors:  Lara Vera; Silvia Oddo; Natascia Di Iorgi; Giorgio Bentivoglio; Massimo Giusti
Journal:  J Med Case Rep       Date:  2016-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.